PepGen 주식 가격. PEPG - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

가격

1.46

매수가

1.46

매도가

1.49

거래량

8,629

0.00 일간 변동폭 0.00

1.16 52주 범위 19.298

market_cap

47.59M

전일 종가

1.37

개장가

최근 거래 시간

350

1.46

(formt)

마지막 거래 시간

21:03:57

재정 규모

VWAP

평균 볼륨(3m)

337,923

발행 주식

32,595,737

배당수익률

주가수익률

-0.57

주당순이익(EPS)

-2.41

매출

순이익

-78.63M

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

pepgen.com

본부

Wilmington, Delaware, USA

설립됨

PepGen Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker PEPG. The last closing price for PepGen was US$1.37. Over the last year, PepGen shares have traded in a share price range of US$ 1.16 to US$ 19.298.

PepGen currently has 32,595,737 shares in issue. The market capitalisation of PepGen is US$44.66 million. PepGen has a price to earnings ratio (PE ratio) of -0.57.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

– Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable...

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled- PepGen Inc. (Nasdaq: PEPG), a...

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0.12	8.9552238806	1.34	1.81	1.24	320975	1.42640803	CS
4	-0.44	-23.1578947368	1.9	2.03	1.16	492943	1.35125113	CS
12	-3.54	-70.8	5	6.85	1.16	337923	2.60393304	CS
26	-8.23	-84.9329205366	9.69	10.14	1.16	206473	3.88906783	CS
52	-12.42	-89.4812680115	13.88	19.298	1.16	159735	7.28980701	CS
156	-14.14	-90.641025641	15.6	20	1.16	124263	9.25187578	CS
260	-14.14	-90.641025641	15.6	20	1.16	124263	9.25187578	CS

PEPG - Frequently Asked Questions (FAQ)

What is the current PepGen share price?

The current share price of PepGen is US$ 1.46

How many PepGen shares are in issue?

PepGen has 32,595,737 shares in issue

What is the market cap of PepGen?

The market capitalisation of PepGen is USD 44.66M

What is the 1 year trading range for PepGen share price?

PepGen has traded in the range of US$ 1.16 to US$ 19.298 during the past year

What is the PE ratio of PepGen?

The price to earnings ratio of PepGen is -0.57

What is the reporting currency for PepGen?

PepGen reports financial results in USD

What is the latest annual profit for PepGen?

The latest annual profit of PepGen is USD -78.63M

What is the registered address of PepGen?

The registered address for PepGen is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the PepGen website address?

The website address for PepGen is pepgen.com

Which industry sector does PepGen operate in?

PepGen operates in the PHARMACEUTICAL PREPARATIONS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
VRMVroom Inc	US$ 24.50 (390.00%)	102
STECSantech Holdings Limited	US$ 3.13 (381.32%)	46.95M
RETOReTo Eco Solutions Inc	US$ 1.17 (188.25%)	21.1M
LINKInterlink Electronics Inc	US$ 13.00 (84.40%)	166
ORISOriental Rise Holdings Ltd	US$ 2.05 (83.04%)	15.49M
PHVSPharvaris NV	US$ 10.01 (-39.30%)	13
EBMTEagle Bancorp Montana Inc	US$ 12.01 (-33.35%)	22
HBNCHorizon Bancorp Inc	US$ 12.30 (-26.65%)	10
WDCWestern Digital Corporation	US$ 52.95 (-22.93%)	6.27k
BOXLBoxlight Corporation	US$ 2.40 (-22.58%)	22.64k
STECSantech Holdings Limited	US$ 3.13 (381.32%)	46.95M
CNEYCN Energy Group Inc	US$ 0.3574 (46.12%)	36.33M
RETOReTo Eco Solutions Inc	US$ 1.17 (188.25%)	21.1M
ORISOriental Rise Holdings Ltd	US$ 2.05 (83.04%)	15.49M
ADTXAditxt Inc	US$ 0.0794 (-13.22%)	13.4M

PEPG new 52 week high

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

PepGen Inc (PEPG)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

PepGen Inc 정보

PEPG 최신 뉴스

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PEPG - Frequently Asked Questions (FAQ)

이동자

PEPG Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

PepGen Inc (PEPG) 시세

PepGen Inc (PEPG)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

PepGen Inc 정보

PEPG 최신 뉴스

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PEPG - Frequently Asked Questions (FAQ)

이동자

PEPG Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거